Multislice Computed Tomography After Left Main Drug-Eluting Stenting

Coronary stenting has become the dominant therapy for patients referred for coronary revascularization. Because of their documented efficacy in reducing instent restenosis (ISR),1–3 drug-eluting stents (DES) are used for this purpose in most percutaneous revascularization procedures. Although intended primarily for use in native, de novo stenoses in coronary vessels 2.5 to 3.5 mm in diameter, DES currently are implanted in a diverse array of patients and lesions, including total occlusions, large and small vessels, acute myocardial infarction, and saphenous vein grafts, despite the absence of convincing trial efficacy data in some of these circumstances.